Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 9/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.55 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | MMP13 | P45452 | 4/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849600 | 0.91 | ITGA4 (0.61) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL4412372 | 0.91 | ITGA4 (0.66) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL4415640 | 0.91 | ITGA4 (0.59) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL3852211 | 0.91 | ITGA4 (0.61) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL3856923 | 0.90 | ITGB1 (0.60) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL4421854 | 0.89 | ITGA4 (0.58) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL3850695 | 0.88 | ITGA4 (0.58) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL3857243 | 0.88 | ITGA4 (0.58) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL3848377 | 0.88 | ITGA4 (0.60) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 | |
| SCHEMBL3849687 | 0.88 | ITGA4 (0.58) | ITGA4ITGB1ITGA5ITGB7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320960-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | claimed |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGA4 6/4885ITGB1 70/4885ITGA5 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.